SpaceOAR in the Media

June 26, 2017

The First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in New Zealand

Kathleen Kilgour Centre is the first cancer center in New Zealand to offer this innovative product to their community.
May 31, 2017

SpaceOAR System Receives Shonin Approval in Japan

Augmenix has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its SpaceOAR® System in Japan.
November 18, 2016

Belfast City Hospital, part of Belfast Health and Social Trust, has become the first NHS site to use SpaceOAR hydrogel from Oncology Systems Limited as part of a trust sponsored clinical trial.

Belfast City Hospital, part of Belfast Health and Social Trust, has become the first NHS site to use SpaceOAR hydrogel from Oncology Systems Limited as part of a trust sponsored clinical trial.
November 13, 2016

Current clinical trials at UTSW are implementing SpaceOAR hydrogel in order to reduce the side effects associated with SBRT

UT Southwestern served as the lead site for a multi-institutional five-year clinical trial, which revealed that Stereotactic Body Radiation Therapy (SBRT) offers a higher cure rate for prostate cancer patients than more traditional approaches.
November 9, 2016

Augmenix Announces New Category 1 CPT® Code from the American Medical Association for Periprostatic Implantation of Biodegradable Material

With the support of the American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA), the American Medical Association (AMA) has granted a Category I, Current Procedural Terminology (CPT) code specifically for periprostatic implantation of biodegradable material. The CPT Code establishes a standard reimbursement pathway for this new procedure which is performed with SpaceOAR® technology.
November 8, 2016

Prostate cancer treatment targets side effects

Radiation treatments for prostate cancer can save lives. But, like other kinds of cancer therapy, it doesn’t come without potential problems that can seriously affect quality of life. Now, men undergoing radiation have a new option — an injectible gel, called SpaceOAR — that can spare surrounding organs.
October 25, 2016

What Every Man Should Know about Radiation Therapy for Prostate Cancer

Dr. Michael Zelefsky Vice Chair of Memorial Sloan Kettering’s Department of Radiation Oncology on the latest radiation treatments for prostate cancer and use of a gel rectal spacer.
October 24, 2016

New technology benefits local prostate cancer patients

Prostate cancer is the one of the most common cancers that face men in America, according to the American Cancer Society. University Hospital in Augusta has started using a new technology to help treat their prostate cancer patients – the SpaceOAR System.
September 28, 2016

‘Good Tool’: Hydrogel Spares Rectum From Radiation

BOSTON — An injected hydrogel that temporarily creates space between the otherwise contiguous rectum and prostate gland continues to benefit patients 3 years after radiation treatment for prostate cancer, according to final safety results from a US multicenter, phase 3 clinical trial. The extended safety benefits included reducing radiotherapy's toxicity and minimizing changes in quality of life (QOL). The hydrogel (SpaceOAR, Augmenix) is a "spacer" that, after injection, remains in place for approximately 3 months and then is eventually absorbed by the body, said lead study author Daniel Hamstra, MD, from Texas Oncology in Irvine. The product was cleared for use in the United States by the Food and Drug Administration last year.
September 25, 2016

ASTRO 2016: Industry Expert Theater

A panel of Dr. Brian Davis, Dr. Michael Zelefsky, Dr. Marcio Fagundes and Dr. Michael Folkert discuss SpaceOAR hydrogel at ASTRO 2016 during an Industry-Expert Theater Event.
September 20, 2016

New prostate cancer treatment at CentraState protects men from radiation effects

We are living during a remarkable age in the battle against cancer. Just a few decades ago, cancer was considered to be a terminal illness. Today, not only can the disease be eradicated, but we can help offset several cancer treatment side effects.
July 20, 2016

Introducing SpaceOAR®: the newest tool in the fight against prostate cancer – Available only at St. Mary’s Regional Cancer Center

St. Mary’s Regional Cancer Center is helping to pioneer a new tool proved to protect prostate cancer patients from the negative effects of radiation therapy. Patients at St. Mary’s are now being injected with SpaceOAR® hydrogel, the first FDA-cleared spacing device to protect the rectum in men undergoing radiation therapy for prostate cancer. The SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, creating space to protect the rectum from radiation exposure.
May 25, 2016

Spartanburg Regional Healthcare System

Cutting-edge CyberKnife technology just got even more advanced for those undergoing treatment for prostate cancer. SpaceOAR improves outcomes and creates the safest environment for patients.
May 5, 2016

PCTRF – Reduce Prostate Cancer Radiation Side Effects

Richard Hsi, MD, Medical Oncologist describes a breakthrough method to reduce side effects when prostate cancer is treated with radiation.
April 13, 2016

VA NY Harbor – Feeling Good, Feeling Good

Two weeks after completion of five SBRT treatments, Mr. Quarles says ‘ “I’m feeling good. I’m feeling good. I just have come in for a two week follow up.”
April 11, 2016

Urology Times – Placement of a hydrogel rectal spacer before RT for prostate Ca

With increasing scrutiny of the sequelae of prostate cancer therapies, placement of a pretreatment spacer may become increasingly prevalent.
April 6, 2016

King5 – Cushioning the effects of prostate radiation

When Garret Ihler underwent radiation for his prostate cancer, he was able to skip the usual side effects, thanks to a product called SpaceOAR Hydrogel.
April 5, 2016

FiercePharma – Augmenix touts study of its rectal spacer to cut radiotherapy effects

Waltham, MA's Augmenix touted its FDA-cleared absorbable spacer for improving prostate cancer radiotherapy.
April 4, 2016

DOTmed – Augmenix announces publication of SpaceOAR pivotal clinical study results

Designed to act as a temporary spacer, the absorbable hydrogel pushes the rectum away from the prostate and reduces rectal radiation injury in men undergoing prostate cancer radiotherapy.
March 31, 2016

Business Wire – Augmenix Announces the Publication of the SpaceOAR® Hydrogel Pivotal Clinical Study Results: Application Technique and Patient Tolerance in Men Undergoing Prostate Cancer Radiotherapy

Using a minimally invasive procedure, SpaceOAR System is injected as a liquid into the space between the prostate and rectum where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy, and then liquefies and is completely absorbed.
March 30, 2016

UroToday – Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications.

We conducted a decision analysis to evaluate the cost effectiveness of a newly FDA approved rectal spacer gel (SpaceOAR) for the reduction of rectal toxicity of prostate radiation therapy (RT).
March 22, 2016

Business Wire – Florida Cancer Affiliates First in the State Certified to Offer New Spacing Device to Benefit Prostate Cancer Patients

“Providing the best possible treatment to patients is our top priority, which is why we are one of the first centers offering SpaceOAR hydrogel.”
March 15, 2016

Future of Radiation Health – What a New Breakthrough Means for Prostate Cancer Care

“In my opinion, the gel spacer is amongst the most important developments in radiation treatment of prostate cancer in the last several years.”
February 10, 2016

Dana-Farber/Brigham and Women’s Cancer Center – Innovative BWF Technique Preserves Rectal Tissue

Radiation Therapy for Prostate Cancer, Innovative BWH Technique Preserves Rectal Tissue.
January 5, 2016

Fox Carolina – Gibbs First in Carolinas with New Technology That Protects Men During Prostate Cancer Radiation Therapy

New SpaceOAR System provides more protection during radiation
January 4, 2016

ECRI Institute Invites Hospitals to Peek Behind the Curtain at the Top 10 Technological Advances to Watch in 2016

#9. Injected Bioabsorbable Hydrogel (SpaceOAR®): An End to Some Radiation Therapy Complications?

Please note that this article was researched and written by ECRI staff and some of the information is dated. There is an incorrect statement in the Cost Equation section “the company has not applied for a New Technology Add-on payment” Correct statement: The company applied for a New Tech APC in June 2015 and CMS issued a new code describing the procedure - C9743, injection/implantation of bulking or spacer material (any type) with or without image guidance, which became effective October 2015.
December 16, 2015

TUCC – New Treatment for Prostate Cancer: SpaceOAR Hydrogel

The Urology Center of Colorado is the first site in Denver to offer radiation therapy patients the SpaceOAR hydrogel before their first treatment.
December 9, 2015

The Urology Center of Colorado First in Denver to Offer New Spacing Device to Benefit Prostate Cancer Patients Undergoing Radiation Therapy

The SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, creating space to protect the rectum from radiation exposure.
October 28, 2015

Augmenix Highlights Rapid U.S. Adoption of SpaceOAR System at ASTRO 2015

October 28, 2015 — Augmenix Inc. showcased the SpaceOAR System at the 57th annual American Society of Therapeutic Radiology and Oncology (ASTRO) meeting, highlighting robust commercial uptake in the United States. An absorbable hydrogel, SpaceOAR technology is designed to create space and protect the rectum in men undergoing prostate cancer radiotherapy. The device received clearance from the U.S. Food and Drug Administration (FDA) in April 2015 and since then, more than 40 cancer treatment centers in 19 states have adopted it [...]
October 19, 2015

SpaceOAR System Session presented at the Industry-Expert Theater – ASTRO 2015

Spacing Organs at Risk – SpaceOAR
Is it a game changer?
October 19, 2015

BusinessWire – Provision Medical Director Speaks at ASTRO on Benefits of SpaceOAR Gel Product

Manufactured by Augmenix, Inc., SpaceOAR is the first product in the United States FDA-approved to protect the rectum in men undergoing prostate cancer radiotherapy.
August 6, 2015

FDA Clears Hydrogel to Improve Prostate Radiotherapy Outcomes

Treatment temporarily expands space between prostate and rectum to reduce radiation dose to rectum April 6, 2015 — Augmenix Inc. announced U.S. Food and Drug Administration (FDA) clearance of the SpaceOAR System, cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa) radiotherapy. Despite many advancements in PCa radiotherapy, the close […]
June 30, 2015

Dr. Sylvester – WFLA

Download this video. SpaceOAR is used in beginning trials and this news coverage from WFLA, Channel 6 in Florida shows an interview with Dr. Sylvester.
April 17, 2015

Applied Radiation Oncology – Augmenix Announces FDA Clearance of SpaceOAR System to Protect the Rectum During RT for Prostate Cancer – Applied Radiation Oncology

Augmenix Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, announced FDA clearance of the SpaceOAR System, the first product in the United States cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa) radiotherapy. Despite many advancements in PCa radiotherapy, the close prostate-rectum […]
April 15, 2015

ITN – FDA Clears Hydrogel to Improve Prostate Radiotherapy Outcomes

April 6, 2015 — Augmenix Inc. announced U.S. Food and Drug Administration (FDA) clearance of the SpaceOAR System, cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa)radiotherapy. Despite many advancements in PCa radiotherapy, the close prostate-rectum proximity makes it challenging to deliver adequate radiation to the prostate without injuring the rectum […]
April 15, 2015

Radiation Therapy News – FDA Clears Augmenix’s SpaceOAR for Prostate Cancer Patients

The U.S. Food and Drug Administration (FDA) has cleared the first spacer for the U.S. market designed to protect the rectum of prostate cancer patients while receiving radiotherapy. The medical device is called SpaceOAR and was developed by Augmenix, Inc. to provide a minimally invasive method of improving cancer radiotherapy outcomes.
April 14, 2015

Medscape – Hydrogel Device Protects Rectum During Prostate Cancer RT

A new device that has just been cleared for commercial use by the US Food and Drug Administration (FDA) offers men with prostate cancer who are undergoing radiotherapy (RT) some protection from collateral damage, specifically to the rectal tissues that are anatomically situated close to the prostate gland. The new device, SpaceOAR (developed by Augmenix […]
April 9, 2015

Urology Times – Product offers benefit to PCa patients undergoing RT

The FDA has granted clearance to the SpaceOAR System, a hydrogel spacer that protects the rectum in men undergoing radiotherapy for prostate cancer. The SpaceOAR (Organ At Risk) System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, creating space to protect the anterior rectum from […]
April 8, 2015

CBS Local 8 News – The Provision Center for Proton Therapy Adopts SpaceOAR

Four patients yesterday received an injection that provides the latest in protection from radiation damage during treatment for prostate cancer.
April 8, 2015

CBS Local 8 News – Provision first proton therapy center using new product to benefit prostate cancer patients

KNOXVILLE, Tenn. (WVLT)– Provision Center for Proton Therapy is helping pioneer a new product that will help further protect prostate cancer patients from the effects of radiation therapy. Augmenix, Inc., privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy. In April, the U.S. Food and Drug Administration approved clearance of […]
April 7, 2015

Medical Physics Web – Augmenix announces FDA clearance of SpaceOAR system

WALTHAM, MA, 2 April 2015 – Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced FDA clearance of the SpaceOAR® System, the first product in the United States cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa) radiotherapy. Despite many […]
April 7, 2015

FDA News – Augmenix’s SpaceOAR Prostate Treatment Receives FDA Clearance

Augmenix announced last Thursday that its SpaceOAR hydrogel system, the first U.S. product capable of protecting the rectum in male patients undergoing prostate cancer radiotherapy, has won FDA de novo clearance. The company plans to launch the product later this year.
April 5, 2015

WKSU 89.7 – Cleveland doctors are the first to try a new prostate cancer treatment

University Hospitals is giving a boost to treatment for one of the most common forms of cancer affecting men. They’re using a new technology designed to improve radiation therapy for prostate cancer patients. For Ohio Public Radio, WCPN’s Kay Colby explains how it works.
April 3, 2015

The Boston Globe – Ten things you may have missed Thursday from the world of business

FDA clears product to aid in prostate cancer treatment A gel from Augmenix Inc. that could improve prostate cancer treatment has won Food and Drug Administration approval. The Waltham company’s SpaceOAR hydrogel, injected before radiation therapy to create a temporary space between the prostate gland and rectum, is the first such product cleared in the […]
April 3, 2015

DOTmed – Augmenix scores FDA nod for prostate cancer spacing device, SpaceOAR System

Augmenix, Inc. announced yesterday that its prostate cancer spacing device, SpaceOAR System, received FDA approval. According to the company, this is the first device cleared in the U.S. that protects the male rectum during radiotherapy treatment. The system works by temporarily moving the anterior rectal wall away from the prostate during radiotherapy in order to […]
April 3, 2015

MSL Group – Augmenix reported FDA clearance of the SpaceOAR system

Augmenix (Waltham, Massachusetts) reported FDA clearance of the SpaceOAR system, the first product in the U.S. cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa) radiotherapy. Despite many advancements in PCa radiotherapy, the close prostate-rectum proximity makes it challenging to deliver adequate radiation to the prostate without injuring the rectum […]
April 3, 2015

Renal & Urology News – FDA Approves Spacing Device for PCa Radiotherapy

The FDA has approved SpaceOAR, a temporary injectable gel that creates a buffer between the prostate gland and the rectum to shield rectal tissue during external beam radiation therapy (EBRT) of prostate cancer. After radiotherapy, the spacer liquefies and is absorbed and cleared from the body in the patient’s urine.
April 3, 2015

Mass Device – Augmenix wins FDA nod for SpaceOar prostate treatment

Augmenix wins de novo clearance from the FDA for its SpaceOar hydrogel, which is designed to help protect surrounding tissue during prostate cancer radiation treatment. FDA clearance in hand, Augmenix is formulating U.S. commercial sales and insurance reimbursement plans for a medical gel designed to help protect the rectum during prostate cancer radiotherapy, CEP John […]
April 3, 2015

AUA – FDA Approves Prostate Cancer Treatment Aid

The Boston Globe (4/3, Newsham) reports that the FDA has approved Augmenix Inc.’s SpaceOAR hydrogel, a prostate cancer treatment aid that is “injected before radiation therapy to create a temporary space between a patient’s prostate gland and his rectum.” The product “could allow oncologists to use higher doses of radiation without harming the rectum,” which […]
April 3, 2015

NBC WKYC- New prostate treatment protects from radiation effects

The FDA approved a new product that protects prostate cancer patients from the side effects of radiation. CHARDON, Ohio — Two days ago, the FDA approved a new product that protects prostate cancer patients from the side effects of radiation. It’s called SpaceOAR (Space Organs At Risk) and it’s a hydrogel that is used as […]
April 2, 2015

The Boston Globe – Augmenix gets FDA approval for prostate cancer treatment aid

By Jack Newsham GLOBE CORRESPONDENT APRIL 02, 2015 Federal regulators have approved a gel by Waltham-based Augmenix Inc. that could improve prostate cancer treatment. The company’s SpaceOAR hydrogel, which is injected before radiation therapy to create a temporary space between a patient’s prostate gland and his rectum, has been cleared by the Food and Drug […]
April 2, 2015

Augmenix Announces FDA Clearance of SpaceOAR System to Protect the Rectum During RT for Prostate Cancer

Augmenix Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, announced FDA clearance of the SpaceOAR System, the first product in the United States cleared as a spacer to protect the rectum in men undergoing prostate cancer (PCa) radiotherapy. Despite many advancements in PCa radiotherapy, the close prostate-rectum […]
April 2, 2015

Augmenix Announces FDA Clearance of SpaceOAR System to Protect the Rectum During RT for Prostate Cancer

WALTHAM, MA USA (Press Release) – April 2, 2015 – (BUSINESS WIRE) First-of-its-kind Treatment Offers Significant Clinical Benefits to Prostate Cancer Patients Undergoing Radiotherapy Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced FDA clearance of the SpaceOAR® System, the first product in the United […]
April 2, 2015

Augmenix Announces FDA Clearance of SpaceOAR System

Despite many advancements in PCa radiotherapy, the close prostate-rectum proximity makes it challenging to deliver adequate radiation to the prostate without injuring the rectum . The SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for PCa, creating space to protect the anterior rectum from radiation exposure. […]
March 27, 2015

Live Science – 5 Reasons Radiation Treatment has Never Been Safer (Op-Ed)

Dr. Edward Soffen is a board-certified radiation oncologist and medical director of the Radiation Oncology Department at CentraState Medical Center’s Statesir Cancer Center in Freehold, New Jersey. He contributed this article to Live Science’s Expert Voices: Op-Ed & Insights. As a radiation oncologist, my goal is to use radiation as an extremely powerful and potent […]